WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6: C12N 5/00	A1	(11) International Publication Number: WO 96/15225 (43) International Publication Date: 23 May 1996 (23.05.96)
(21) International Application Number: PCT/US((22) International Filing Date: 21 December 1994 (2)		RU, UA, European patent (AT, BE, CH, DE, DK, ES, FR
(30) Priority Data: 08/341,409 16 November 1994 (16.11.9	4) U	Published S With international search report.
(71) Applicant: YISSUM RESEARCH DEVELOR COMPANY OF THE HEBREW UNIVERSING JERUSALEM [-/IL]; 46 Jabotinsky Street, P.O. B 91042 Jerusalem (IL). (71) (72) Applicant and Inventor: MITRANI, Eduardo [-Wessex Road, Newton, MA 02159 (US).	TY C sox 427	F D,
(74) Agents: SUNSTEIN, Bruce, D. et al.; Bromberg & 11th floor, 125 Summer Street, Boston, MA 021 (US).	Sunstei 110-161	8
(54) Title: IN VITRO MICROORGANS (57) Abstract		

....

An in vitro microorgan culture, method for forming the same and uses thereof are provided. The cells in the culture, for example hair follicles, are capable of proliferation and/or homeostasis over an extended period of time while maintaining their natural affinity for neighboring cells. The microorgan cultures are characterized by a surface area to volume ratio of at least 1.5mm⁻¹.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger :
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
		IE	Ireland	NZ	New Zealand
BG	Bulgaria	π	kaly	PL	Poland
BJ	Benin	JP	•	PT	Portugal
BR	Brazil	_	Japan Vanna	RO	Romania
BY	Belarus	KE	Kenya	RU	Russian Federation
CA	Canada	KG	Kyrgystan	SD	Sudan
CF	Central African Republic	KP	Democratic People's Republic		
CG	Congo		of Korea	SE	Sweden
СН	Switzerland	KR	Republic of Korea	SI	Slovenia
CI	Côte d'Ivoire	KZ	Kazakhstan	SK	Slovakia
СМ	Cameroon	u	Liechtenstein	SN	Senegal
CN	China	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
cz	Czech Republic	ĹŸ	Latvia	TJ	Tajikistan
DE	<u> </u>	MC	Monaco	TT	Trinidad and Tobago
DK.	Germany	MD	Republic of Moldova	UA	Ukraine
	Denmark	MG	Madagascar	US	United States of America
ES	Spain		•	U2	Uzbekistan
FI	Finland	ML	Mali	VN	Viet Nam
FR	Prance	MN	Mongolia	***	A 100 1 100 11
~ .	A-b				

5

15

- 1 -

IN VITRO MICRO-ORGANS

TECHNICAL PIELD

The present invention relates to growing microorgan cultures having a surface area to volume index of at least approximately 1.5mm⁻¹ and being capable of cell proliferation and homeostasis for extended periods of time.

BACKGROUND OF THE INVENTION

Eukaryotic cell culture was first achieved in the early 1950s. Since that time, a wide range of transformed and primary cells have been cultivated using a wide variety of media and defined supplements such as growth factors and 20 hormones as well as undefined supplements such as sera and other body extracts. For example, fibroblasts taken from a part of an animal such as the skin, can be routinely cultivated through many cell generations as karyotypically diploid cells or indefinitely as established cell lines.

25 Epithelial cells however have morphological and proliferative properties that differ from fibroblasts are more difficult to cultivate. Indeed, in vitro, epithelial cells are commonly overgrown by fibroblasts when the two cells are grown together.

A diverse range of media have been developed for growing epithelial cells in a clonally competent manner. In some cases these cells can produce at least partially differentiated epithelium. Approaches to cultivation of epithelial cells in particular skin epithelia

(keratinocytes) have included the following: cultivating cells on a feeder layer of lethally irradiated fibroblasts (Rheinhardt et al. 1975, Cell 6:331-343); cultivating keratinocytes on semi-synthetic collagen matrices (Eisenberg 1994, US Patent 5, 282,859; Bell 1990, EP 0361957); adding

biological extracts including pituitary extracts and sera to specialized media; and utilizing a range of growth supplements including epidermal growth factor, and insulin (Boisseau et al. 1992, J. Dermatol. Sci. 3(2):111-120; Willie 1994, U.S. Patent No. 5,292,655).

The skin.

Numerous attempts have been described for growing epithelial cells in such a way as to mimic human skin for 10 purposes of wound treatment, in particular treatment of The skin consists of two types of tissue. are: (1) the stroma or dermis which includes fibroblasts that are loosely dispersed within a high density collagen matrix as well as nerves, blood vessels and fat cells; 15 (2) the epidermis which includes an epidermal basal layer of tightly packed, actively proliferating immature epithelial cells. As the cells of the basal layer replicate, some of the young cells remain in the basal layer while others migrate outward, increase in size and eventually develop an 20 envelop resistant to detergents and reducing agents. In humans, a cell born in the basal layer takes about 2 weeks to reach the edge or outer layer after which time the cells die and are shed. The skin contains various structures including hair follicles, sebaceous glands and sweat glands. 25 Hair follicles are formed from differentiating keratinocytes that densely line invaginations of the epidermis. ended vesicles that formed from such invaginations collect and concentrate the secreted keratin and a hair filament results. Alternatively, epidermal cells lining an 30 invagination may secrete fluids (sweat gland) or sebum (sebaceous gland). The regulation of formation and proliferation of these structures is unknown.

The constant renewal of healthy skin is accomplished by a balanced process in which new cells are being produced and aged cells die. There is a need to understand how this precise regulation comes about in order to counteract abnormal events occurring in aging, and also through disease

and trauma that disrupt the balance. For example, psoriatic cells proliferate and die at an accelerated pace taking only about 15% of the time normally observed. Epidermal neoplasia arises when the epidermal cells multiply without control and rapidly overtake the number of cells normally dying. In chronic wounds, normal epidermal and dermal regeneration fails to occur.

Cultivation of skin in vitro.

- Numerous attempts at growing skin in vitro have been undertaken. These attempts almost all include the step of separating the keratinocytes in the epidermis from fibroblasts and fat cells in the dermis. Where separation of keratinocytes is not performed, whole organs have been used.
- 15 Attempts to cultivate organs in vitro have been limited to incubating organs in a serum containing medium (Li et al. 1991, Proc. Natl. Acad. Sci. 88(5):108-112). Where isolation of keratinocytes is performed, these cells are grown in a manner that permits the formation of a stratified
- epidermis. The epidermis prepared in this manner lacks hair follicles and sweat glands and the natural relationship between the epidermis and the dermis is not preserved. Cultivation methods including growing keratinocytes on non viable fibroblasts (Rheinwald et al. 1975, Cell 6:331-343);
- or placing the keratinocytes from the animal on a dermal substrate of collagen and fibroblasts that is synthetic or has been derived from an alternative source from that of the epidermis (Sugihara et al. 1991, in vitro Cell Dev. Biol. 27:142-146; Parenteau et al. 1991, J. Cell Biochem.
- 30 45(3):245-251).

Most existing in vitro models of the epidermis lack hair follicles, sweat glands and sebaceous glands (for a review of epidermal cell culture, see Coulomb et al. 1992, Pathol. Biol. Paris, 40(2):139-146). Exceptions include the gel-supported skin model of Li et al. (1991) who utilized skin explants with dimensions of 2 x 5mm² and 2.0 mm thick

that remained viable for several days in the presence of serum containing media.

It would be desirable to have an in vitro model of the skin in a serum free environment where the natural intercellular relationships that occur in vivo are maintained so as to more accurately study how skin is formed and remains viable. For example, insights into how hair follicle formation occurs would have significant therapeutic applications including treatment for balding men, for patients undergoing chemotherapy and for skin grafting.

An in vitro model of the skin that closely mimics the properties of skin in vivo would have utility in screening assays in which compounds could be tested for their ability to repair or damage the skin (Kao et al. 1985, Toxicol.

- 15 Appl. Pharmacol. 81:502-516; Goldberg ed. 1989, Alternative Methods in Toxicology, vol. 7, pp. v-vi, New York:Liebert). Requirements of a reproducible model for screening might include consistency in tissue architecture and nutritional environment in vitro, as well as prolonged viability and proliferation of cultures beyond 24 hours to observe
 - threshold effects of compounds being screened. This level of consistency cannot be achieved in the presence of undefined media supplements such as sera or tissue extracts that vary between batches and cannot be adequately
- controlled. The dependence of a model on external growth supplements such as growth factors is also undesirable as growth factors or hormones may be included among the compounds to be tested. At present, existing in vitro skin models either require exogenous factors (Boyce et al. 1983,
- 30 J. Invest. Dermatol. 81:33-4) or serum (Li et al. 1991, Proc. Natl. Acad. Sci. 88(5):108-112) or are only viable for short periods of time.

Epithelia.

35 The skin is one example of an epithelial tissue supported by stromal tissue containing fibroblasts.

Epithelial tissues are found in every part of the body where

an interface between an organ and the environment arise.

Epithelial cells cycle continuously in an uninjured body and form the covering tissue for all the free surfaces in the body including the skin. In some cases, such as in the pancreas, the epithelial cells line numerous invaginations and secrete enzymes into open spaces that enable the organ to function. The lung is another example of a highly invaginated organ, each invagination in the lung being lined with epithelial cells through which air diffuses from the environment in to the body. Once again, these epithelial cells have characteristic properties. The lining of the gut is also composed of specialized epithelial cells that not only form a barrier but contain specialized structures for selectively absorbing food. All the epithelia are supported by a stroma of connective tissue.

There is a need for in vitro methods of culturing and maintaining organ cultures in which the cells preserve their naturally occurring intracellular relationships for extended periods of time. The availability of a tissue model in which differentiation, cell proliferation and cell homeostasis occurs would have utility in understanding the mechanisms by which organs are maintained in a healthy state and consequently how abnormal events may be reversed.

25 SUMMARY OF THE INVENTION

This invention satisfies the above needs. A novel in vitro micro-organ culture is provided that in a preferred embodiment comprises a population of animal cells outside of an animal, corresponding to cells inherent in an organ, the 30 cells being grouped so as to preserve the natural affinity of one cell to another, the dimensions of the cell grouping having a surface area to volume index of at least approximately 1.5mm⁻¹, and being capable of at least one of cell proliferation and cellular homeostasis, the population of animal cells being maintainable in a nutrient medium for a period of time in excess of 24 hours.

A further embodiment of the invention includes a method for forming an in vitro microorgan culture, comprising obtaining a population of animal cells outside of an animal, corresponding to cells inherent in an organ, the cells being grouped so as to preserve the natural affinity of one cell to another, the dimensions of the cell grouping having a surface area to volume index of at least approximately 1.5mm⁻¹, being capable of at least one of cell proliferation and cellular homeostasis and placing the cells in nutrient medium for a period of time in excess of 24 hours.

A further embodiment of the invention includes a method of screening a compound for biological activity which comprises forming an in vitro microorgan culture as described above, exposing the culture to the compound and measuring a change in any of cell proliferation, cellular homeostasis or cell differentiation in the presence of the compound.

A further embodiment of the invention includes a method of repairing a non-healing wound in an animal subject, having the following steps including selecting a population of cells from an animal subject; sectioning the population of cells into a plurality of segments so that the surface area to volume index is at least approximately 1.5mm⁻¹; and applying the population of cells of step (b) so as to replace or supplement the endogenous tissue.

A further embodiment of the invention includes a method directed to modifying cell proliferation in a mammalian tissue, comprising; identifying a compound capable of modifying normal proliferation and homeostasis of a microorgan culture as described above, and administering the compound to an animal subject.

BRIEF DESCRIPTION OF THE DRAWINGS

These and other features, aspects and advantages of the present invention will become better understood with

reference to the following description, appended claims and accompanying drawing where

Fig. 1 is a diagrammatic representation of a microorgan depicting the dimensions that determine Aleph where x= 5 thickness and a= width of the tissue.

Fig. 2a is a histogram showing cell proliferation in a guinea pig micro-organ culture as determined by BrdU labelling after incubation for different time periods.

Fig. 2b is a histogram showing cell proliferation in a 10 human back skin micro-organ culture as determined by BrdU labelling after incubation of cultures for 1-8 days.

Fig. 2c is a micrograph showing immunofluorescence corresponding to replicating cells of mouse x50 (a), guinea pig x75 (b) human foreskin x50 (c) and human foreskin x 75 (d).

Fig. 2d. Transverse section of human micro-organ explants. (mag x75) showing tissue architecture at zero (a), three(b) and six(d) days in culture.

Fig. 3 is a histogram demonstrating the effect on 20 epidermal proliferation of varying thickness (x) of guinea pig skin microorgan cultures using BrdU incorporation where (a) has been kept constant at 4mm.

Fig. 4 is a micrograph showing immunofluorescence corresponding to proliferating cells in pancreas derived 25 microorgan cultures (mag x75).

Fig. 5 is a histogram showing amounts of insulin released by adult pig pancreas microorgan cultures.

Fig. 6 is a histogram showing ³H-Thymidine incorporation in proliferating cells in microorgan cultures 30 of the colon, liver, kidney, duodenum and esophagus, at 3 days, 4 days and 6 days of "in vitro" cultivation.

Fig. 7a is a micrograph showing active proliferation of hair follicles in micro-organ cultures as determined by immunofluorescence. Magnification (a) \times 40 ,(b) and (c) \times 75.

Fig. 7b is a histogram showing the size distribution of hair shafts at the beginning and end of the microculture.

Fig. 8 is a histogram showing the inhibition of mitogenesis in microorgan cultures in the presence of 2.5ng/ml TGF- β in guinea-pig skin cultures

Fig. 9 is a diagrammatic representation of a microorgan seplant for treatment of chronic skin ulcers showing incomplete sectioning of tissue slices so as to maintain a structure that can be readily manipulated in vivo.

Fig. 10 is a photograph of the surface of a mouse after removal of a piece of normal skin and subsequent replacement 10 with a micro-organ culture showing healing and generation of new hair shafts in the implant that has become incorporated in the mouse host.

DETAILED DESCRIPTION OF SPECIFIC ENBODIMENTS

15 The present invention is directed to an in vitro model system in which epithelial cells undergo at least one of cell proliferation and cellular homeostasis according to that found in nature. Cellular homeostasis is defined here and in the claims as an equilibrium between cell proliferation and cell loss in which the tissue as a whole remains viable but may not necessarily grow despite continued growth of individual cells within the tissue. In

this context, cell loss may arise for example from cell death or cell sloughing. For example, gut derived epithelia contain a very active proliferative population of cells that divide every 24 hours while maintaining a constant size.

A population of cells is defined here and in the claims as a number of cells of one or more types that may coexist together.

The surface area to volume index is defined here and in the claims as Aleph where: Aleph = 1/x+1/a > 1.5mm⁻¹ and x= tissue thickness and a= width of tissue in millimeters as shown in Fig 1.

The third dimension has been ignored in determining the surface area to volume index because variation in the third dimension causes ratiometric in both volume and surface

5

area. However, when determining Aleph, a and x should be defined as the two smallest dimensions of the tissue slice.

The surface area to volume index.

A unique aspect of the invention is the similar availability of nutrients to all cells in the tissue by The availability of nutrients to cells in a three dimensional structure is similar to that of cells in a monolayer according to the invention. The diffusion of 10 nutrients to every cell in a three dimensional organ culture requires a minimum level of accessibility to each cell absent specialized delivery structures or synthetic substrates. This accessibility can be maintained if Aleph is at least approximately 1.5 mm⁻¹ where Aleph is an index 15 calculated from the thickness and the width of the tissue.

Examples of Aleph are provided in Table 1 where for example, a tissue having a thickness (x) of 0.1mm and a width (a) of 1mm would have an Aleph index of 11. In example 1, the tissue has x=0.3mm and a=4mm so that Aleph = 3.48. 20 In Example 3, x is varied and a is constant at 4mm. It can be seen from Figure 3, that proliferative activity is substantially reduced as the thickness of the explant increases. Accordingly, at 900 µm thickness, the number of proliferating cells in a microorgan culture is about 10 fold 25 less then in tissue from a similar source having a thickness of 300 μ m. The Aleph index for a tissue having a thickness of 900 μ m is 1.36, below the minimum described here and in the claims whereas the aleph index for tissue having a thickness of 300µm is 3.58mm⁻¹ which is well within the range defined 30 here and in the claims.

TABLE 1

Different values for the surface area to volume ratio index "Aleph", as a function of a (width) and x (thickness) in mm1

	a (mm) / *(mm)	1	2	3	4	5
	0.1	11	10.5	10.33	10.25	10.2
Ì	0.2	6	5.5	5.33	5.25	5.2
5	0.3	4.3	3.83	3.67	3.58	3.53
	0.4	3.5	3	2.83	2.75	2.7
•	0.5	3	2.5	2.33	2.25	2.2
	0.6	2.66	2.16	2	1.91	1.87
	0.7	2.4	1.92	1.76	1.68	1.63
10	0.8	2.25	1.75	1.58	1.5	1.45
	0.9	2.11	1.61	1.44	1.36	1.31
	1	2	1.5	1.33	1.25	1.2
	1.2	1.83	1.3	1.16	1.08	1.03
	1.3	1.77	1.26	1.1	1.02	0.96
15	1.6	1.625	1.13	0.96	0.88	0.83
	2	1.5	1	0.83	0.75	0.7

Source of microorgans capable of homeostasis and proliferation in vitro.

In an embodiment of the invention, populations of cells are grouped in a manner that preserves the natural affinity 5 of one cell to another. For example, in skin micro-organ cultures, keratinocytes of the epidermis remain associated with the stroma and the normal tissue architecture is preserved including the hair follicles. Such an association facilitates intercellular communication. Many types of 10 communication takes place among animal cells. This is particularly important in differentiating cells where induction is defined as the interaction between one (inducing) and another (responding) tissue or cell, as a result of which the responding cells undergo a change in the 15 direction of differentiation. Moreover, inductive interactions occur in embryonic and adult cells and can act to establish and maintain morphogenetic patterns as well as induce differentiation (Gurdon (1992) Cell 68: 185-199).

The micro-organ cultures prepared according to the
invention as described in Example 1, comprise a population
of cells grouped in a manner that may include a plurality of
layers so as to preserve the natural affinity of one cell to
another. The proliferation of individual cells or groups of
cells can be observed and followed by autoradiography or
immunofluorescence. (Example 2, Fig. 2).

Micro-organ cultures from animals including adult human skin, mouse, guinea pig and rat skin have been isolated and grown for up to 21 days in culture. However, it is within the scope of the invention to maintain cultures for extended 30 periods of time beyond 21 days.

Furthermore, it is within the scope of the invention to form micro-organ cultures from a wide range of animals. The range of animals are merely exemplified but is not limited to the sample provided in Example 2.

Micro-organ cultures were prepared from skin (Examples 1 2,3, 7 and 8) and also from organs including the mammalian pancreas, liver, kidney, duodenum, esophagus and bladder

(Example 4, 5 and 6). Similarly, microorgan cultures of epithelia from mammalian cornea, kidney, breast tissue and various gut derived tissues in addition to the esophagus such as intestine and colon may also be prepared using the methods of the invention. Indeed, it is within the scope of the invention to isolate and maintain microorgan cultures from any site which contains an epithelial stromal architecture within the body.

10 The growth medium.

There are a large number of tissue culture media that exist for culturing cells from animals. Some of these are complex and some are simple. While it is expected that microorgan cultures may grow in complex media, it has been shown here that the cultures can be maintained in a simple medium such as Dulbecco's Minimal Essential Media. Furthermore, although the cultures may be grown in a media containing sera or other biological extracts such as pituitary extract, it has been shown here that neither sera nor any other biological extract is required. Moreover, the organ cultures can be maintained in the absence of sera for extended periods of time. In preferred embodiments of the invention, growth factors are not included in the media during maintenance of the cultures in vitro.

The microorgan cultures may be maintained in any suitable culture vessel such as a 24 or 96 well microplate and may be maintained at 37°C in 5% CO2. The cultures may be shaken for improved aeration, the speed of shaking being for example 12 rpm.

30

25

Measuring the biological properties of micro-organ culture

The microorgan cultures of the present invention derived from normal tissue have been shown to maintain a state of homeostasis with proliferation of constituent cells without overall growth of the tissue.

Methods of measuring cell proliferation are well known in the art and most commonly include determining DNA

synthesis characteristic of cell replication. There are numerous methods in the art for measuring DNA synthesis, any of which may be used according to the invention. In an embodiment of the invention, DNA synthesis has been determined using a radioactive label (³H-thymidine) or labelled nucleotide analogues (brdU) for detection by immunofluorescence.

Micro-organ cultures can be formed and maintained not only by the proliferation of mature cells but also by the 10 active participation of precursor cells including in some instances, embryonic cells. The micro-organ cultures have been shown to represent a suitable environment for preserving and facilitating the natural evolution of these precursor cells. For example, the immature cells of the 15 basal layer have been observed to become mature keratinocytes in skin microorgan cultures. (Fig 3(b)). Similarly, embryonic pancreatic cells can provide a mature pancreatic epithelium in microorgan cultures. maturation of precursor cells and their subsequent 20 functioning as adult cells can be monitored by measuring secretion of specialized products such as specific keratins in epidermal cells and insulin, Glut 2 and glucagon in pancreatic epithelia.

The micro-organ cultures prepared according to the
invention preserve the normal tissue architecture that is
present in vivo. This includes the maintenance of hair
follicles, sweat glands and sebaceous glands in skin microrgans in vitro according to their normal occurrence in vivo
(Examples 7 and 8 and Figs 7a, 7b and 8). Because these
cultures can be maintained in controlled and uniform
conditions and yet they closely resemble tissue in vivo,
they provide a unique opportunity to observe, measure and
control natural phenomena and the perturbation of natural
phenomena arising from disease, aging or trauma.

Furthermore, the ready availability of techniques to study
individual cells at identified sites on the culture, provide

insights into the

functioning of individual components of the tissue as they interact with each other as well as the whole tissue.

Applications of microorgan cultures

5 Applications of the microorgan cultures include the following:

- (a) identification of factors involved in normal homeostasis of tissues and cells;
- (b) the effect on the normal homeostasis of tissues and 10 cells of changes in the environment of the cells including changes in nutrients and the presence of potentially toxic agents;
- (c) the pathway of changes in the tissues and cells that are triggered at the beginning and during pathogenesis 15 or trauma;
 - (d) identification of repair mechanism that reverse the adverse effects in an altered environment associated with pathogenesis or trauma;
- (e) developmental regulation of cells that20 differentiate during the normal homeostasis of the tissue;
 - (f) developmental regulation of specialized structures within the tissue such as hair follicles; and
- (g) organ supplementation where pieces of an individual's organ remains but are insufficient for
 25 replacing or regenerating damaged tissue such as occurs in patients with chronic skin ulcers which have healing deficiencies caused by inappropriate blood supply, or where the local skin is unable to heal such as in the condition known as type 1 or type 11 diabetes.

Regulation of wound healing

30

Repair of skin lesions is known to be a highly complex process that includes primary epithelial cell migration as well as replication of epidermal cells in response to molecular signals from underlying connective tissue. Skin micro-organ cultures have been used here as a model for wound healing. Under controlled culture conditions, factors

controlling healing can be carefully monitored. Furthermore, since the culture is isolated from the natural blood supply, analysis of the healing process can be done without the additional complexity of blood borne factors or 5 cells. Normal epidermis has a low mitotic activity with cells cycling every 200-300 hours. When the epidermis is wounded, a burst of mitotic activity takes place so that the cells divide up to 10 times faster depending on the conditions and severity of the wound (Pinkus H., J.Invest. 10 Dermatol. 16: 383-386 (1951)). In Example 2, we have shown that the microorgan cultures show increased proliferation of up to 10 fold for several days. In this example, the edge of a wound is comparable to the microorgan culture. This increased proliferation mimics the events that are 15 associated with wounding and provide a unique opportunity to study the process of wound healing. We have demonstrated in vivo that microoexplants can be applied to chronic wounds (Example 9) and can form a viable implant capable of growing hair (Example 10).

20

Regulation of tumor formation and growth

A preferred embodiment of the invention is directed to inhibition of epithelial tumor formation and growth. Tumor formation arises as a consequence of alterations in the control of cell proliferation and disorders in the interactions between cells and their surroundings. The patterns of growth of a variety of rapidly growing, transplantable and malignant tumors of epithelial origin are organized tissues with characteristic histological patterns.

The establishment of the basic pattern depends first on the connective tissue adjacent position of the mitotic cells, a medial sheath of differentiated aging cells and an inner mass of dying cells. Except that the tumor forms a cyst instead of a sheet, the cells are stratified in a manner that is similar to the epidermis. In this situation, cell production exceeds cell loss.

Data is presented here (Example 9, Fig 9) in which microorgan cultures of the skin have been used for screening compounds for biological activity. In this example, TGF-β was tested and found to act as an inhibitor of cell proliferation. This model more accurately reproduces the structure of in vivo skin than any previous model. Activin has also been shown to inhibit proliferation of epithelial cells. This protein is a member of the TGF-β superfamily and as such suggests that there may be other members of this family that play a role in inhibition of proliferation of epithelial cells. The data suggests a role for proteins in the TGF-β family as significant regulators of epidermal homeostasis and in inhibiting epithelial tumor formation and growth in vivo.

15

Example 1: Preparation of microorgan cultures of epidermis.

Fresh skin was obtained after surgery, cleaned from underlying fat tissue and cut into 0.4 x 5 cm flaps, which are then transversely sectioned, using a tissue chopper or other suitable cutting means into 300 µm sections under sterile conditions so that the final tissue segments had dimensions of 4mm in width and 0.3mm in thickness (see Fig 1). These microorgans were placed in a 24-well microplate in 400µl of DMEM in the absence of serum under 5 CO₂ at 37°C, under constant shaking at 12x rpm for periods of 1 to 8 days. Twenty micro-explants were grown per well.

Example 2: Measurement of the proliferation of cells in vitro in epidermis culture derived from mice, guinea pigs and humans.

Microorgan cultures were prepared according to Example 1 5 and proliferation of cells was measured by analyzing the amount of DNA synthesis as follows:

Mouse skin and guinea pig skin were grown for 2 days and human foreskin was grown for 4 days after which brdU was added to the medium in a final concentration of 100µM for 3 10 hrs, followed by fixation of the cells in 4% formaldehyde. After fixation, the cultures were stained with goat anti-brdU antibodies followed by anti-goat-FITC labeled IgG. Histological preparations were embedded in epon after fixation in 4% formaldehyde and cut into 3µm slices and stained with methylene blue.

It was found that the fraction of cells synthesizing DNA in vitro after 2 to 4 days in culture increased up to 10 fold compared with the values observed in vivo, after which the rate of DNA synthesis gradually decreased but remained 20 high for up to 10 days in culture (see Figs. 2a. b. c). Even at six days in culture, the cells maintained a steady state of proliferation and differentiation so that the tissue architecture was preserved (Fig 2d).

25 Example 3: Measurement of the proliferation of cells within a microorgan of various sizes.

Guinea pig micro organs were prepared as in Example 1. Whole thickness skin strips 4mm in width were sectioned into explants of varying thicknesses including slices of 300, 300, 450, 600, 700, 900, 1200 and 3000μm thickness. These slices were placed individually into wells containing serum free medium for 2 days. BrdU was added for 4 hrs before termination at a final concentration of 100 μM. The explants were then fixed in 4% formaldehyde and stained with goat antibodies to BrdU followed with a anti-goat IgG FITC labelled antibody preparation. The results are shown in Fig 3. The amount of brdU incorporation as a factor of the

35

number of cells /unit tissue is significantly reduced as the thickness of the explants increase.

Frample 4: Preparation of microorgan cultures
from the pancreas and measurement of
cell proliferation within the culture.

Guinea-pig pancreas was removed and then cut into sections of 300µm in thickness, 4mm in width and 2mm in depth. The micro-explants were grown in culture for several time periods from 2 to 18 days. Seven micro-organs were placed in each of 96 wells of a plate in 150µl DMEM in the absence of serum under 5% CO₂ at 37°C under constant shaking at 12 RPM. BrdU was added 3 hrs before termination at a final concentration of 100µM and the explants were then fixed in 4% formaldehyde and stained with goat antibodies to BrdU followed by anti-goat-FITC labeled IgG. Fig. 4 illustrates that cells in the pancreas derived microorgans are actively proliferating.

20 <u>Example 5</u>: Preparation of microorgan cultures from the pancreas and measurement of insulin secretion into the medium.

Adult pig pancreas microorgan cultures were prepared as in the previous examples for skin. Pancreases were removed, 25 cut with scissors to an approximate depth of 2mm and sliced into sections 300µm thick having a width of 4mm. The microcultures were grown for 14 days in serum free medium. Every two days, the medium was removed and fresh medium added. Collected media was assayed for insulin content using standard radioimmunoassay methods. (fig 5)

Example 6: Preparation of microorgan cultures from the liver, kidney, duodenum, esophagus and bladder and measurement of cell proliferation within the culture.

Guinea-pig microorgan micro-cultures from several epithelial containing organs were prepared as in previous examples for skin. Organs were removed and with scissors, were cut to an appropriate width of 2mm and sliced into sections of 300μm thick. The microcultures were incubated

for 3,4,and 6 days in serum free medium. 12 hours before termination of the experiment, ³H-thymidine was added to the cultures of explants. At termination, the tissue was fixed, rinsed several times and counted in a scintillation counter.

The results are shown in Fig 6 where all tissues exhibit active proliferation which continues through 6 days as determined by uptake of ³H-thymidine.

Example 7: Proliferation of hair follicles in vitro. Epidermis was prepared according to Example 1 and 10 incubated for 2 days. BrdU was added 3 hrs before termination of incubation. Cells were fixed in 4% formaldehyde and stained with goat anti-brdU antibodies followed by anti-goat-FITC labelled IgG. Intact hair 15 follicles that were present in vivo in their normal surroundings could be maintained under precisely controlled culture conditions, without the need of add serum or any other exogenous factor. Hair follicle cells in these microorgans were found to proliferate vigorously for several 20 days under the conditions of the present method as indicated by the large number of hair follicles cells that incorporated brdU (Fig 7a). The size distribution of hair shafts at time zero of a micro-organ guinea pig culture and after 2 weeks is shown in Fig 7b. The medium was exchanged 25 every two days. Hair shaft size have been arbitrarily classified as small, medium and large. After 9 days in culture, there is a clear shift in size distribution so that the percentage of small hairs decreased from 64% to 28%, while large shafts which were not present at the 30 beginning of the culture now represented 30% of the shaft population.

Example 8: Preparation of a screening assay for measuring the effect of an external agent on cell proliferation.

The cultures were prepared and maintained in defined medium in similar growth conditions as described in Example 1. Control samples were analyzed by immunocytochemistry to

35

determine that the microorgan culture was maintained in a manner that was similar to that occurring in vivo.

Duplicated samples of skin micro-cultures were treated with TGF-β at 2.5 ng/ml. A quantitative analysis of the number of BrdU labelled cells / explant was performed according to Example 2. Greater then 90% inhibition of DNA synthesis was observed in the presence of TGF-β compared with controls (Fig. 8).

10 Example 9: A method of treating patients with chronic non-healing skin ulcers.

According to this method, a small-area of normal, uninvolved skin autograph is removed from the patient and full-thickness microexplants of 4mm in width and 0.3mm thick 15 is prepared as described in Example 1. The preparation however differs from Example 1 in that the sectioning into 0.3mm slices is deliberately incomplete so that a series of sections are held together as indicated in Fig 9, the upper epidermal layers including the stratum corneum. The design 20 of this implant is directed to permitting the nutrients to reach all the cells but maintaining the tissue slices in a manipulatable format. The patient's wound is cleaned and surrounding skin edges are removed. The area devoid of skin is then carefully covered by the micro-explants, which are 25 placed on the wound such that the non-sectioned edge is facing outermost and the opposing sectioned pieces are suspended in the fluid within the wound. Sufficient micro-explants are prepared to substantially cover the wounded area. The treated region is then covered with a 30 suitable dressing and allowed to heal.

Example 10: Proliferation of hair follicles in vivo.

An in vivo animal experiment was performed where a 1cm² area of skin was removed from a mouse and incompletely

35 microsectioned so that the stratum corneum of the whole skin area was left intact as described in Example 9. The microorgan was reimplanted into its original position in the mouse, stitched and allowed to heal. The implant remained

viable, became incorporated into the animal tissue and new hair shafts grew from the implant after 1-2 weeks in culture. (see fig 10).

Although certain preferred embodiments of the present invention have been described, the spirit and scope of the invention is by no means restricted to what is described above.

I claim:

- The culture according to claim 1, wherein the
 population of cells correspond to a section of an epithelium and an underlying stroma.
- The culture according to claim 2, wherein the organ is selected from the group consisting of skin, bladder,
 cornea, breast, gut derived tissue and pancreas.
 - 4. The culture according to claim 2, wherein the epithelium is pancreatic epithelium and the stroma is pancreatic stroma.
- 5. The culture according to claim 2, wherein the organ is pancreas and the population of cells are formed from precursor cells capable of differentiating into pancreas.
- 6. The culture according to claim 2, wherein the epithelium is epidermis formed from keratinocytes and the stroma is dermis formed from fibroblasts.
- 7. The culture according to claim 6, wherein the 35 keratinocytes further comprise a basal lamina and an epidermal layer; and the fibroblasts in the dermis are contained in an extracellular matrix.

10

- 8. The culture according to claim 2, wherein the organ is skin and the population of cells are formed from precursor cells capable of differentiating into skin.
- 5 9. The culture according to claim 2, wherein the epithelium contains at least one invagination therein.
 - 10. The culture according to claim 9, wherein the epithelium is an epidermis.
- 11. The culture according to claim 10, wherein the cells lining the invagination secrete compositions selected from the group consisting of keratin, sebum and sweat.
- 15 12. The culture according to claim 11, wherein the invagination is a hair follicle.
- 13. The culture according to claim 9, wherein the cells lining the invagination secrete compositions associated with 20 glandular secretions, such compositions including proteins.
 - 14. The culture according to claim 1, wherein the nutrient medium is deficient in biological extracts.
- 25 15. The culture according to claim 14, wherein the nutrient medium is deficient in serum.
 - 16. The culture according to claim 15, wherein the nutrient medium is Dulbecco's minimal essential medium.
 - 17. The culture according to claim 14, wherein the cells are capable of cell proliferation and cellular homeostasis for a period of time in excess of 7 days.
- 35 18. The culture according to claim 1, wherein the cells are inherent in a healthy organ.

30

PCT/US94/14822

25

- 19. The culture according to claim 1, wherein the cells are inherent in a diseased organ
- 20. The culture according to claim 1, wherein the cells 5 inherent in the organ comprise malignant cells.
 - 21. The culture according to claim 1, wherein the cells inherent in the organ comprise hyperproliferative cells.
- 22. A method for forming an in vitro microorgan culture, comprising:
 - (a) obtaining a population of animal cells outside of an animal, corresponding to cells inherent in an organ, the cells being grouped so as to preserve the natural
- 15 affinity of one cell to another, the dimensions of the cell grouping having a surface area to volume index of at least approximately 1.5mm⁻¹, and being capable of at least one of cell proliferation or cellular homeostasis; and
- (b) placing the cells in nutrient medium for a 20 period of time in excess of 24 hours.
 - 23. The method according to claim 22, wherein the population of cells correspond to a section of an epithelium and an underlying stroma.
 - 24. The method according to claim 23, wherein the organ is selected from the group consisting of skin, pancreas, bladder, cornea, breast, gut derived tissue and pancreas.
- 30 25. The method according to claim 23, wherein the organ is pancreas and the epithelium is derived from precursor pancreatic cells.
- 26. The method according to claim 23, wherein the 35 epithelium comprises a basal lamina and an epidermal layer formed from a population of keratinocytes and the stroma comprises an extracellular matrix and fibroblasts.

PCT/US94/14822

- 27. The method according to claim 23, wherein the organ is skin and the population of cells are formed from precursor cells, capable of differentiating into skin.
- 28. The method according to claim 23, further comprising an epithelium containing at least one invagination therein.
 - 29. The method according to claim 28, wherein the epithelium is an epidermis.

10

- 30. The method according to claim 29, wherein the cells lining the invagination secrete compositions are selected from the group consisting of keratin, sebum and sweat.
- 15 31. The method according to claim 30, wherein the invagination is a hair follicle.
- 32. The method according to claim 28, wherein the cells lining the invagination secrete compositions, the 20 compositions including proteins.
 - 33. The method according to claim 22, wherein the nutrient medium is deficient in biological extracts.
- 25 34. The method according to claim 33, wherein the nutrient medium is deficient in serum.
 - 35. The method according to claim 34, wherein the nutrient medium is Dulbecco's minimal essential medium.

30

UCDOCID- - NICO - 0815995&1 | -

- 36. The method according to claim 33, wherein the cells are capable of cell proliferation and cellular homeostasis for a period of time in excess of 7 days.
- 35 37. The method according to claim 22, wherein the population of cells are cells inherent in a healthy organ.

30

- 38. The method according to claim 22 wherein the population of cells are cells inherent in a diseased organ
- 39. The method according to claim 22, wherein the 5 population of cells comprise malignant cells.
 - 40. The method according to claim 22, wherein the population of cells comprise hyperproliferative cells.
- 10 41. A method of screening a compound for biological activity, comprising:
 - (a) forming an in vitro microorgan culture according to claim 22;
 - (b) exposing the culture to the compound; and
- (c) measuring a change in any of; cell proliferation, cellular homeostasis, cell differentiation or function in the presence of the compound.
- 42. The method according to claim 41, wherein the 20 compound is a therapeutic agent.
 - 43. The method according to claim 41, wherein the compound is a random peptide
- 25 44. The method according to claim 41, wherein the compound is a toxin
 - 45. The method according to claim 41, wherein the compound is a growth factor.
 - 46. The method according to claim 41, wherein the compound is a growth factor inhibitor
- 47. The method according to claim 41, wherein the 35 external agent is a cosmetic.

PCT/US94/14822

10

30

- 48. The method according to claim 41, wherein the compound is an antisense molecule.
- 49. The method according to claim 41, further comprising 5 step (d) of reversing an effect of a first compound with a second compound.
 - 50. The method according to claim 41, wherein the population of cells is healthy.
- 51. The method according to claim 41, wherein the population of cells is abnormal.
- 52. The method according to claim 41, wherein step (C)
 15 further comprises identifying dividing cells or
 differentiating cells with a marker.
 - 53. A method of repairing a non-healing wound in an animal subject, comprising;
- 20 (a) selecting an a population of cells from an animal subject;
 - (b) sectioning the population of cells into a plurality of segments so that the surface area to volume index is at least approximately 1.5mm⁻¹; and
- 25 (c) applying the population of cells of step (b) so as to cover the wound.
 - 54. The method of claim 53, wherein the sectioning of the tissue is incomplete.
 - 55. The method of claim 53, wherein the non-healing wound is an ulcer.
- 56. A method of modifying cell proliferation in a
 35 mammalian tissue, comprising; identifying a compound capable of modifying normal proliferation and homeostasis of a

microorgan culture of claim 1, and administering the compound to an animal subject.

- 57. A method according to claim 56, wherein the compound 5 is activin A.
 - 58. The method according to claim 56, wherein the compound is $TGF-\beta$.
- a population of animal cells outside of an animal, corresponding to cells inherent in an organ, the cells being grouped so as to preserve the natural affinity of one cell to another, and being capable of at least one of cellular proliferation or cellular homeostasis, the population of animal cells being maintainable in a serum free nutrient media for a period of time in excess of 24 hours.
- 60. An in vitro micro-organ culture comprising the 20 invention as described and illustrated in the specification.




FIG. 1




FIG. 2A




FIG. 2B

SUBSTITUTE SHEET (RULE 26)

FIG. 2C-A

FIG. 2C-B




FIG. 2C-C

FIG. 2C-D



FIG. 2D-A




FIG. 2D-B



FIG. 2D-C




FIG. 3




FIG. 4A





FIG. 4B



SUBSTITUTE SHEET (RULE 26)




FIG. 6




FIG. 7A-A

FIG. 7A-B

FIG. 7A-C




FIG. 7B




FIG. 8




FIG. 9

SUBSTITUTE SHEET (RULE 26)



FIG. 10

SUBSTITUTE SHEET (RULE 26)

Intern. nal Application No PCT/US 94/14822

	PCT/US S		14/14822			
A. CLASSI IPC 6	ification of subject matter C12N5/00					
	•	·				
	o International Patent Classification (IPC) or to both national classif	fication and IPC				
B. FIELDS	SEARCHED ocumentation searched (classification system followed by classification	ion symbols)				
IPC 6	C12N					
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched						
Electromic d	lata base consulted during the international search (name of data bas	ic and, where practical, search terms used)			
	· .		·			
C. DOCUM	ENTS CONSIDERED TO BE RELEVANT					
Category *		elevant passages	Relevant to claim No.			
x	R. IAN FRESHNEY 'Culture of Anim	nal Cells,	1-60			
	a Manual of Basic Technique' 1987 , ALAN R. LISS, INC. , NEW Y see page 297 - page 307 see page 302					
x	THE JOURNAL OF INVESTIGATIVE DERM vol. 95, no. 4, 1990 NEW YORK, pages 397-402,	1-60				
	KONDO, S. ET AL 'Long-term culturabbit skin: effect of EGF on epistructure in vitro' see page 397, column 2	·				
x	WO,A,91 12334 (CETUS CORPORATION) see the whole document) 1991	57			
		-/	Relevant to claim No. 1-60 1-60 1-60 1-60 1-60 1-60 1-60 1-7 Interpretation annex. In the principle or theory underlying the considered to be experiented to be considered to be experiented to be exper			
ļ						
X Furt	ther documents are listed in the continuation of box C.	X Patent family members are listed	I in annex.			
		"T" later document published after the in or priority date and not in conflict to	with the application but			
		invention "X" document of particular relevance; th	e claimed invention			
filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another establish on the remediate of the second of the seco		myolve an inventive step when the c "Y" document of particular relevance; th	document is taken alone ne claimed invention			
"O" document referring to an oral disclosure, use, exhibition or other means "O" document referring to an oral disclosure, use, exhibition or other means "O" document is combined with one or means other means.			more other such docu-			
'P' docum						
	actual completion of the international search					
ļ	7 July 1995					
Name and	mailing address of the ISA European Patent Office, P.B. 5818 Patentiaan 2 NI 2220 HV Ritweik	Authorized officer				
	NL - 2280 HV Rijswijk Td. (+31-70) 340-2040, Tz. 31 651 epo nl. Faz: (+31-70) 340-3016	Fernandez y Bran	as,F			

intern. nal Application No PCT/US 94/14822

C.(Cretien	PCT/US 94/14822				
Category	Gitation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.			
X.	EP,A,O 271 211 (COLLAGEN CORPORATION) 1988 see the whole document	58			
A	THE AMERICAN JOURNAL OF PATHOLOGY, vol. 142, no. 6, 1993 HAGERSTOWN M.D., pages 1813-1822, VARANI, J. ET AL 'All-trans retinoic acid and extracellular Ca2+ differentially influence extracellular matrix production by human skin in organ culture' see the whole document	1-60			
	•				
ĺ					
	•				
		·			
	•				
·					
,,					
		·			
	·				
	•				

It. national application No. PCT/US 94/ 14822

Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet) This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons: 53-58 1. X Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely: Remark: Although claim 53-58 are directed to a method of treatment of human/animal body the search has been carried out and based on the alleged effects of the composition. because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a). Claims Nos.: Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet) This International Searching Authority found multiple inventions in this international application, as follows: As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims. As all searchable claims could be searcnes without effort justifying an additional fee, this Authority did not invite payment of any additional fee. As only some of the required additional search fees were untely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.: 3. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: The additional search fees were accompanied by the applicant's protest. Remark on Protest No protest accompanied the payment of additional search fees.

finformation on patent family members

Intern. nal Application No PCT/US 94/14822

Patent document cited in search report	Publication date	Patent family member(s)		Publication date	
WO-A-9112334		AU-A- EP-A-	7321891 0515494	03-09-91 02-12-92	
EP-A-271211	15-06-88	US-A- AU-B- AU-A- DE-A-	4816442 591358 8067987 3781250	28-03-89 30-11-89 12-05-88 24-09-92	
	•	ES-T- JP-A-	2032272 63211236	16-01-94 .02-09-88	

This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

□ BLACK BORDERS
□ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
□ FADED TEXT OR DRAWING
□ BLURRED OR ILLEGIBLE TEXT OR DRAWING
□ SKEWED/SLANTED IMAGES
□ GRAY SCALE DOCUMENTS
□ GRAY SCALE DOCUMENTS
□ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY

IMAGES ARE BEST AVAILABLE COPY.

☐ OTHER:

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.